On July 10, 2020, Stoke Therapeutics filed a prospectus for a $400 million mixed shelf offering of its common stock, preferred stock, debt securities, warrants, and subscription rights and units. The company's stock is traded on the Nasdaq Global Select Market under the symbol “STOK.” On July 8, 2020, the last reported sales price for Stoke Therapeutics' common stock was $23.40 per share. Wilson Sonsini Goodrich & Rosati advised Stoke Therapeutics on all intellectual property aspects related to the offering.

Stoke Therapeutics is pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression. The company develops antisense oligonucleotide medicines that increase gene expression to treat genetic epilepsies and other severe monogenic diseases, including genetic conditions affecting the central nervous system, eye, liver, and kidney. Stoke Therapeutics believes its proprietary technology platform, Targeted Augmentation of Nuclear Gene Output, or TANGO, will allow it to deliver disease-modifying therapies in a highly precise, durable, and controlled manner.

The Wilson Sonsini team that advised Stoke Therapeutics on all IP matters related to the offering includes Vern Norviel, Louis Lieto, Chris McAndrew, Wei Huang, and Swati Sharma.

For more information, please see Stoke Therapeutics' S3 filing with the SEC.